Antimicrobial therapy for chronic bacterial prostatitis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 8, 2013, Pages

  Perletti, Gianpaolo ^a,b   Marras, Emanuela ^a   Wagenlehner, Florian M E ^c   Magri, Vittorio ^d  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b GHENT UNIVERSITY   (Belgium)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d PARKINSON INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; CARBENICILLIN; CEFALEXIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; LEVOFLOXACIN; LOMEFLOXACIN; MACROLIDE; MINOCYCLINE; NORFLOXACIN; OFLOXACIN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; VARDENAFIL; QUINOLONE DERIVATIVE;

ANTIMICROBIAL THERAPY; ARTHRALGIA; BACKACHE; BACTERIAL INFECTION; BONE PAIN; CHLAMYDIASIS; CHRONIC BACTERIAL PROSTATITIS; CHRONIC PROSTATITIS; COUGHING; DIZZINESS; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERGLYCEMIA; INSOMNIA; LEUKOPENIA; LIVER TOXICITY; LONG TERM CARE; LUNG TOXICITY; MICTURITION DISORDER; MYALGIA; NEUROTOXICITY; PELVIC PAIN; PERINEAL PAIN; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RHINITIS; SCROTAL PAIN; SEMEN ABNORMALITY; SEXUAL DYSFUNCTION; SKIN TOXICITY; SYMPTOM; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT INFECTION; UREAPLASMA INFECTION; URINARY FREQUENCY; URINARY URGENCY; XEROSTOMIA; CHRONIC DISEASE; MALE; META ANALYSIS; MICROBIOLOGY; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); BACTERIAL INFECTIONS; CHLAMYDIA INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHLAMYDIA INFECTIONS; CHRONIC DISEASE; FLUOROQUINOLONES; HUMANS; MACROLIDES; MALE; PROSTATITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84891835641     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009071.pub2     Document Type: Review

References (96)

1. Aliaev LuG, Vinarov AZ, Akhvlediani ND. Wardenafil in combined treatment of patients with chronic bacterial prostatitis. Urologiia (Moscow, Russia: 1999) 2008;6:52-5. [PUBMED: 19256057]
2. Bundrick W, Heron SP, Ray P, SchiffWM, Tennenberg AM, Wiesinger BA, et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology 2003;62(3):537-41. [PUBMED: 12946763]
3. Hernandez Bustillo M, Calderon F, Marina JM, Barreda R. [Lomefloxacino s. trimetoprim/sulfametoxazol en el tratamiento de la prostatitis bacteriana cronica]. Boletín del Colegio Mexicano de Urología 1997;14:94-7.
4. Cai T, Mazzoli S, Bechi A, Addonisio P, Mondaini N, Pagliai RC, et al. Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study. International Journal of Antimicrobial Agents 2009;33(6):549-53. [PUBMED: 19181486]
5. Cai T, Mazzoli S, Addonisio P, Boddi V, Geppetti P, Bartoletti R. Clinical and microbiological efficacy of prulifloxacin for the treatment of chronic bacterial prostatitis due to Chlamydia trachomatis infection: results from a prospective, randomized and open-label study. Methods and Findings in Experimental and Clinical Pharmacology 2010;32(1):39-45. [PUBMED: 20383345]
6. Cox CE. Ofloxacin in the management of complicated urinary tract infections, including prostatitis. The American Journal of Medicine 1989;87(6C):61S-8S. [PUBMED: 2690622]
7. Giannarini G, Mogorovich A, Valent F, Morelli G, De Maria M, Manassero F, et al. Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. Journal of Chemotherapy 2007;19(3):304-8. [PUBMED: 17594926]
8. KoffW. Clinical trial comparing lomefloxacin and ofloxacin in the treatment of chronic bacterial prostatitis [Estudo comparativo entre lomefloxacina e ofloxacina no tratamento da prostatite bacteriana cronica]. Revista Brasileira de Medicina 1996;53(1/2):88-91.
9. Naber KG. Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis. International Journal of Antimicrobial Agents 2002;20(1):18-27. [PUBMED: 12127707]
10. Ohkawa M, Yamaguchi K, Tokunaga S, Nakashima T, Shoda R. Antimicrobial treatment for chronic prostatitis as a means of defining the role of Ureaplasma urealyticum. Urologia Internationalis 1993;51(3):129-32. [PUBMED: 8249222]
11. Paulson DF, Zinner NR, Resnick MI, Childs SJ, Love T, Madsen PO. Treatment of bacterial prostatitis. Comparison of cephalexin and minocycline. Urology 1986;27(4):379-87. [PUBMED: 3515737]
12. Skerk V, Schonwald S, Krhen I, Markovinovic L, Barsic B, Marekovic I, et al. Comparative analysis of azithromycin and clarithromycin efficacy and tolerability in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Journal of Chemotherapy 2002;14(4):384-9. [PUBMED: 12420857]
13. Skerk V, Schonwald S, Krhen I, Banaszak A, Begovac J, Strugar J, et al. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. International Journal of Antimicrobial Agents 2003;21(5):457-62. [PUBMED: 12727080]
14. Skerk V, Krhen I, Lisic M, Begovac J, Roglic S, Skerk V, et al. Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis. International Journal of Antimicrobial Agents 2004;24(2):188-91. [PUBMED: 15288321]
15. Skerk V, Krhen I, Lisic M, Begovac J, Cajic V, Zekan S, et al. Azithromycin: 4.5-or 6.0-gram dose in the treatment of patients with chronic prostatitis caused by Chlamydia trachomatis--a randomized study. Journal of Chemotherapy 2004; Vol. 16, issue 4:408-10. [PUBMED: 15332719]
16. Skerk V, Marekovic I, Markovinovic L, Begovac J, Skerk V, Barsic N, et al. Comparative randomized pilot study of azithromycin and doxycycline efficacy and tolerability in the treatment of prostate infection caused by Ureaplasma urealyticum. Chemotherapy 2006;52(1):9-11. [PUBMED: 16340190]
17. Smith JW, Jones SR, Reed WP, Tice AD, Deupree RH, Kaijser B. Recurrent urinary tract infections in men. Characteristics and response to therapy. Annals of Internal Medicine 1979;91(4):544-8. [PUBMED: 384858]
18. Zhang ZC, Jin FS, Liu DM, Shen ZJ, Sun YH, Guo YL. Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients. Asian Journal of Andrology 2012;14(6):870-4.
19. Ateya A, Fayez A, Hani R, Zohdy W, Gabbar MA, Shamloul R. Evaluation of prostatic massage in treatment of chronic prostatitis. Urology 2006;67(4):674-8. [PUBMED: 16566972]
20. Baert L, Mattelaer J, de Nollin P. Treatment of chronic bacterial prostatitis by local injection of antibiotics into prostate. Urology 1983;21(4):370-5. [PUBMED: 6836824]
21. Barbalias GA, Nikiforidis G, Liatsikos EN. Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics. The Journal of Urology 1998;159(3):883-7. [PUBMED: 9474175]
22. Brannan W. Treatment of chronic prostatitis. Comparison of minocycline and doxycycline. Urology 1975;5(5):626-31. [PUBMED: 1093309]
23. Cai T, Wagenlehner FM, Mazzoli S, Meacci F, Mondaini N, Nesi G, et al. Semen quality in patients with Chlamydia trachomatis genital infection treated concurrently with prulifloxacin and a phytotherapeutic agent. Journal of Andrology 2011;33(4):615-23. [PUBMED: 21979301]
24. Childs SJ, Wells WG, Chubb JM. Ceftazidime, an open randomized comparison of 3 dosages for genitourinary infections. The Journal of Urology 1983;130(3):495-7. [PUBMED: 6350616]
25. Colleen S, Mardh PA. Effect of metacycline treatment on non-acute prostatitis. Scandinavian Journal of Urology and Nephrology 1975;9(3):198-204. [PUBMED: 813297]
26. Cox CE, Childs SJ. Treatment of chronic bacterial prostatitis with temafloxacin. The American Journal of Medicine 1991;91(6A):134S-9S. [PUBMED: 1662884]
27. Deng C, Zheng B, She S. [Clinical study of zinc for the treatment of chronic bacterial prostatitis]. Zhonghua Nan Ke Xue = National Journal of Andrology 2004;10(5):368-70. [PUBMED: 15190832]
28. Gleckman R, Crowley M, Natsios GA. Therapy of recurrent invasive urinary-tract infections of men. The New England Journal of Medicine 1979;301(16):878-80. [PUBMED: 384251]
29. Hu WL, Zhong SZ, He HX. Treatment of chronic bacterial prostatitis with amikacin through anal submucosal injection. Asian Journal of Andrology 2002;4(3):163-7. [PUBMED: 12364969]
30. Kim YJ, Ryu JK, LEE HJ, Choi WS, Suh JK. Comparison of the efficacy of transperineal intraprostatic injection and oral administration of fluoroquinolone in men with chronic bacterial prostatitis-seminal vesiculitis. Korean Journal of Urology 2006;47:1185-90.
31. Kozdoba AS, Popov SV, Ivanchenko LP. [Complex therapy of chronic bacterial prostatitis using matrix-urologist laser therapy]. Urologiia (Moscow, Russia: 1999) 2007;5:51, 53-5. [PUBMED: 18257156]
32. Kunishima Y, Takeyama K, Takahashi S, Matsukawa M, Koroku M, Tanda H, et al. Gatifloxacin treatment for chronic prostatitis: a prospective multicenter clinical trial. Journal of Infection and Chemotherapy 2008;14(2):137-40. [PUBMED: 18622677]
33. Lee SD, Lee SJ, Hwang TK, Yoon DK, Lee KS, Sung LH, et al. Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice. International Journal of Antimicrobial Agents 2006;28 Suppl 1:S108-12. [PUBMED: 16844352]
34. Liao D, Chen Z, Deng Z, Wang D. Xinxibao for the treatment of chronic bacterial prostatitis. Zhonghua Nan Ke Xue = National Journal of Andrology 2004;10(9):676-7. [PUBMED: 15497709]
35. Martino P, Ricapito V, Sblendorio D, Disabato G, Battaglia M, Carrieri G, et al. Transrectal echography in the evaluation of the effects of endocavitary laser therapy in patients with bacterial prostatitis [L'ecografia transrettale nella valutazione degli effetti indotti dalla laser terapia endocavitaria in pazienti portatori di prostatite batterica]. Archivio Italiano di Urologia, Andrologia 1993;65(4):391-6. [PUBMED: 8353547]
36. Nickel JC, Xiang J. Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis. The Journal of Urology 2008;179(4):1391-5. [PUBMED: 18289570]
37. Paglia M, Peterson J, Fisher AC, Qin Z, Nicholson SC, Kahn JB. Safety and efficacy of levofloxacin 750 μg for 2 weeks or 3 weeks compared with levofloxacin 500 μg for 4 weeks in treating chronic bacterial prostatitis. Current Medical Research and Opinion 2010;26(6):1433-41. [PUBMED: 20394471]
38. Panagopoulos P, Antoniadou A, Kanellakopoulou K, Tsiodras S, Katsarolis I, Papadopoulos A, et al. Fluoroquinolone treatment of chronic bacterial prostatitis: a prospective cohort study. Journal of Chemotherapy 2009;21(3):317-21. [PUBMED: 19567353]
39. Sabbaj J, Hoagland VL, Cook T. Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men. Scandinavian Journal of Infectious Diseases. Supplementum 1986;48:48-53. [PUBMED: 3490684]
40. Schaeffer AJ, Wu SC, Tennenberg AM, Kahn JB. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. The Journal of Urology 2005;174(1):161-4. [PUBMED: 15947609]
41. Shafik A. Perineal versus anal submucosal injection for drug administration in treatment of chronic prostatitis. Urology 1992; Vol. 39, issue 3:297. [PUBMED: 1546432]
42. Shen B, Jin X, Cai S, Chen J, Chen G, Zhao W, et al. Effect and mechanism of alpha1-adrenoceptor blocker combined with antibiotics for chronic prostatitis. Zhonghua Nan Ke Xue = National Journal of Andrology 2004;10(7):518-20. [PUBMED: 15354524]
43. Smelov V, Gorelov A, Smelova N, Krylova T. Single-drug or combined antibacterial therapy in the treatment of patients with chronic prostatitis and Chlamydia trachomatis?. International Journal of Antimicrobial Agents 2004;23 Suppl 1:S83-7. [PUBMED: 15037333]
44. Trapeznikova MF, Morozov AP, Dutov VV, Urenkov SB, Pozdniakov KV, Bychkova NV. An open randomized comparative trial of efficacy and safety of selective alpha-adrenoblocker setegis (terazosin) in therapy of patients with chronic bacterial prostatitis. Urologiia (Moscow, Russia: 1999) 2007;2:33-7. [PUBMED: 17578197]
45. Vicari E. Effectiveness and limits of antimicrobial treatment on seminal leukocyte concentration and related reactive oxygen species production in patients with male accessory gland infection. Human Reproduction 2000;15(12):2536-44. [PUBMED: 11098023]
46. Vickovic N, Skerk V, Granic J, Vargovic M, Pasini M, Turcic P, et al. Metronidazole 1.5 gram dose for 7 or 14 days in the treatment of patients with chronic prostatitis caused by Trichomonas vaginalis: A randomized study. Journal of Chemotherapy 2010; Vol. 22, issue 5:364-5. [PUBMED: 21123162]
47. Wedren H. On chronic prostatitis with special studies of Staphylococcus epidermidis. Scandinavian Journal of Urology and Nephrology. Supplementum 1989;123:1-36. [PUBMED: 2483757]
48. Xu JC, Lu QM, Fu LJ, Chen YP. Qianlie Jiedu capsule combined with rufloxacin for chronic prostatitis: a randomized double-blind controlled clinical trial. Zhonghua Nan Ke Xue = National Journal of Andrology 2010;16(2):183-6. [PUBMED: 20369705]
49. Yavaşçaoglu I, Çamlikiyi H, Oktay B, Şimşek Ü, Özyurt M. Percutaneous suprapubic transvesical route: a new and comfortable method of intraprostatic injection. Urologia Internationalis 1998;60(4):229-34. [PUBMED: 9701736]
50. Zhang W, Liu Z, Dong H, Sun C. Related pathogen examinations and therapeutic choices for chronic prostatitis following sexually transmitted diseases. Zhonghua Nan Ke Xue = National Journal of Andrology 2004;10(4):275-7, 281. [PUBMED: 15148924]
51. Drasa K, Tartari F. Cefuroxime axetil vs. Ceftriaxone and both combination in treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. European Urology Supplements 2009;8(4):260.
52. Aagaard J, Gasser T, Rhodes P, Madsen PO. MICs of ciprofloxacin and trimethoprim for Escherichia coli: influence of pH, inoculum size and various body fluids. Infection 1991;19 Suppl 3:S167-9. [PUBMED: 2055655]
53. Bartoletti R, Cai T, Mondaini N, Dinelli N, Pinzi N, Pavone C, et al. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. The Journal of Urology 2007;178(6):2411-5. [PUBMED: 17937946]
54. Berges R, Oelke M. Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older. World Journal of Urology 2011;29(2):171-8. [PUBMED: 21221974]
55. Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N. Penetration of antimicrobial agents into the prostate. Chemotherapy 2003;49(6):269-79. [PUBMED: 14671426]
56. Clemens JQ, Meenan RT, O'Keeffe Rosetti MC, Gao SY, Calhoun EA. Incidence and clinical characteristics of National Institutes of Health type III prostatitis in the community. The Journal of Urology 2005;174(6):2319-22. [PUBMED: 16280832]
57. Clemens JQ, Markossian T, Calhoun EA. Comparison of economic impact of chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis/painful bladder syndrome. Urology 2009;73(4):743-6. [PUBMED: 19193408]
58. Cohen JM, Fagin AP, Hariton E, Niska JR, Pierce MW, Kuriyama A, et al. Therapeutic intervention for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a systematic review and meta-analysis. PLoS One 2012;7(8):e41941. [PUBMED: 22870266]
59. Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. The Journal of Urology 1998;159(4):1224-8. [PUBMED: 9507840]
60. DalhoffA, Schubert S, Ullmann U. Effect of pH on the in vitro activity of and propensity for emergence of resistance to fluoroquinolones, macrolides, and a ketolide. Infection 2005;33 Suppl 2:36-43. [PUBMED: 16518710]
61. Daniels NA, Link CL, Barry MJ, McKinlay JB. Association between past urinary tract infections and current symptoms suggestive of chronic prostatitis/chronic pelvic pain syndrome. Journal of the National Medical Association 2007;99(5):509-16. [PUBMED: 17534008]
62. Drach GW, Fair WR, Meares EM, Stamey TA. Classification of benign diseases associated with prostatic pain: prostatitis or prostatodynia?. The Journal of Urology 1978; Vol. 120, issue 2:266. [PUBMED: 671653]
63. Ejike CE, Ezeanyika LU. Prevalence of chronic prostatitis symptoms in a randomly surveyed adult population of urban-community-dwelling Nigerian males. International Journal of Urology 2008;15(4):340-3. [PUBMED: 18380824]
64. Erickson BA, Schaeffer AJ, Van Le B. Chronic prostatitis. Clinical Evidence 2008;5:1802. [PUBMED: 19450305]
65. Ferris JA, Pitts MK, Richters J, Simpson JM, Shelley JM, Smith AM. National prevalence of urogenital pain and prostatitis-like symptoms in Australian men using the National Institutes of Health Chronic Prostatitis Symptoms Index. BJU International 2010;105(3):373-9. [PUBMED: 19549116]
66. Foulds G, Madsen P, Cox C, Shepard R, Johnson R. Concentration of azithromycin in human prostatic tissue. European Journal of Clinical Microbiology & Infectious Diseases 1991;10(10):868-71. [PUBMED: 1722460]
67. Gesu GP, Eftimiadi C, Debbia E, Schito GC. Effects of changes in pH, medium and inoculum size on the in vitro activity of different quinolone and fluoroquinolone antibiotics against urinary pathogens. Drugs Under Experimental and Clinical Research 1987;13(2):79-84. [PUBMED: 3556122]
68. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians?. BMJ 2008;336(7651):995-8. [PUBMED: 18456631]
69. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org (accessed 8 February 2011).
70. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
71. Kamberi M, Tsutsumi K, Kotegawa T, Kawano K, Nakamura K, Niki Y, et al. Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. Antimicrobial Agents and Chemotherapy 1999;43(3):525-9. [PUBMED: 10049262]
72. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999; Vol. 282, issue 3:236-7. [PUBMED: 10422990]
73. Krieger JN, Lee SW, Jeon J, Cheah PY, Liong ML, Riley DE. Epidemiology of prostatitis. International Journal of Antimicrobial Agents 2008;31 Suppl 1:S85-90. [PUBMED: 18164907]
74. Liang CZ, Li HJ, Wang ZP, Xing JP, Hu WL, Zhang TF, et al. The prevalence of prostatitis-like symptoms in China. The Journal of Urology 2009;182(2):558-63. [PUBMED: 19524948]
75. Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clinical Infectious Diseases 2010;50(12):1641-52. [PUBMED: 20459324]
76. McNaughton-Collins M, Joyce GF, Wise M, Pontari MA. Prostatitis. In: Litwin MS, Saigal CS editor(s). Urologic Diseases in America. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. NIH Publication No. 07-5512. Washington, DC: US Government Printing Office, 2007:11-39.
77. Meares EM Jr. Long-term therapy of chronic bacterial prostatitis with trimethoprim-sulfamethoxazole. Canadian Medical Association Journal 1975;112(13 Spec No):22-5. [PUBMED: 236820]
78. Mehik A, Hellstrom P, Lukkarinen O, Sarpola A, Jarvelin M. Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study. BJU International 2000;86(4):443-8. [PUBMED: 10971269]
79. Mehik A, Hellstrom P, Sarpola A, Lukkarinen O, Jarvelin MR. Fears, sexual disturbances and personality features in men with prostatitis: a population-based cross-sectional study in Finland. BJU International 2001;88(1):35-8. [PUBMED: 11446842]
80. Naber KG, Sorgel F. Antibiotic therapy - rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 2003;35(5):331-5. [PUBMED: 14535866]
81. Naber KG. Management of bacterial prostatitis: what's new?. BJU International 2008;101 Suppl 3:7-10. [PUBMED: 18307679]
82. Nickel JC, Downey J, Hunter D, Clark J. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. The Journal of Urology 2001;165(3):842-5. [PUBMED: 11176483]
83. Nickel JC, Shoskes D, Wang Y, Alexander RB, Fowler JE Jr, Zeitlin S, et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome?. The Journal of Urology 2006;176(1):119-24. [PUBMED: 16753385]
84. Nickel JC, Patel M, Cameron M. Chronic prostatitis/chronic pelvic pain syndrome: finding a way forward in the United Kingdom: report from the first United Kingdom symposium on chronic prostatitis, January 30, 2008, London, United Kingdom. Reviews in Urology 2008;10(2):160-3. [PUBMED: 18660861]
85. Nickel JC, Shoskes DA. Phenotypic approach to the management of the chronic prostatitis/chronic pelvic pain syndrome. BJU International 2010;106(9):1252-63. [PUBMED: 20946349]
86. Njue C. Statistical considerations for confirmatory clinical trials for similar biotherapeutic products. Biologicals 2011;39(5):266-9. [PUBMED: 21807534]
87. Perletti G, Wagenlehner FM, Naber KG, Magri V. Enhanced distribution of fourth-generation fluoroquinolones in prostatic tissue. International Journal of Antimicrobial Agents 2009;33(3):206-10. [PUBMED: 19091519]
88. Pontari MA, Joyce GF, Wise M, McNaughton-Collins M. Prostatitis. The Journal of Urology 2007;177(6):2050-7. [PUBMED: 17509285]
89. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
90. Rizzo M, Marchetti F, Travaglini F, Trinchieri A, Nickel JC. Prevalence, diagnosis and treatment of prostatitis in Italy: a prospective urology outpatient practice study. BJU International 2003;92(9):955-9. [PUBMED: 14632854]
91. Schaeffer AJ. NIDDK-sponsored chronic prostatitis collaborative research network (CPCRN) 5-year data and treatment guidelines for bacterial prostatitis. International Journal of Antimicrobial Agents 2004;24 Suppl 1:S49-52. [PUBMED: 15364307]
92. Shoskes DA. Use of antibiotics in chronic prostatitis syndromes. The Canadian Journal of Urology 2001;8 Suppl 1:24-8. [PUBMED: 11442994]
93. Shoskes DA, Nickel JC, Rackley RR, Pontari MA. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer and Prostatic Diseases 2009;12(2):177-83. [PUBMED: 18645581]
94. Stamey TA. Prostatitis. Journal of the Royal Society of Medicine 1981;74(1):22-40. [PUBMED: 7007638]
95. Wagenlehner FM, Weidner W, Naber KG. Therapy for prostatitis, with emphasis on bacterial prostatitis. Expert Opinion on Pharmacotherapy 2007;8(11):1667-74. [PUBMED: 17685884]
96. Wallner LP, Clemens JQ, Sarma AV. Prevalence of and risk factors for prostatitis in African American men: the Flint Men's Health Study. The Prostate 2009;69(1):24-32. [PUBMED: 18802926]